Xenome is a biotechnology company focused on the discovery and development of peptide-based therapeutics. 

The Company's value lies in its unique expertise in peptide chemistry and its ability to translate the evolutionary advantages inherent in venom peptides into highly bioactive, drug-like molecules.  Xenome's discovery platform is based on a proprietary library of venom peptides.

Latest News